AI IN DRUG DISCOVERY USA

Artificial Intelligence (AI) is leading technological advancements in the pharmaceutical sector, poised to transform pre-clinical drug discovery by reducing costs by up to 40% and creating a market valued at up to $50 billion in the next decade. This transformative period is upon us, and the AI in Drug Discovery conference offers a unique opportunity to hear directly from experts and gain strategies to enhance your operations.

Scheduled for October 2024 in the United States, the AI in Drug Discovery Conference comes after a successful event in March 2024 in the UK. Since then, the industry has achieved a groundbreaking milestone: the first wholly AI-discovered and designed drug is now in Phase 2 clinical trials.

The conference is driven by the industry's shift towards personalized therapies and novel drug candidates. Innovations in automation, in-silico modeling, and machine learning are increasing the efficiency of the drug discovery process, propelling growth in this expanding field and revolutionizing modern healthcare.

Why Attend?

1. Gain valuable insights from leading biotechs and major pharmaceutical companies on drug target selection.

2. Explore neural networks, digital twins, new drug designs, and in-silico modeling to expand your drug portfolio.

3. Understand the benefits of machine learning from molecule design to clinical trial selection, with a focus on patient-centric considerations.

4. Discuss the best uses and potential impacts of Generative AI, especially in light of the launch of Chat GPT.

This conference will help you navigate through the hype surrounding AI and reveal effective strategies to harness its power for achieving tangible and transformative outcomes in drug design and discovery. Benefit from the expertise of diverse speakers who are at the forefront of AI applications in the pharmaceutical sector, pushing the field towards clinical trials and introducing new, transformative drugs to the market.

Who Should Attend?

The conference is ideal for companies aiming to expedite the delivery of therapeutics to patients, thereby extending healthy longevity. Attendees will learn how to build an AI ecosystem by combining internal and external resources and partners to discover new treatment methods, design novel molecules, optimize existing treatments, and reduce the cost and time of drug development.

Collaboration and Learning

Share ideas, collaborate, and learn from both successes and challenges in data science and drug discovery—a fast-changing field that requires interdisciplinary skills and experience. Mature your company's approach to AI and machine learning applications to overcome major challenges and avoid pitfalls that have hindered previous initiatives. Benchmark your pipeline against the latest understandings of the strengths and weaknesses in leveraging these tools.

Key Takeaways:

- Insight into the true nature of major challenges in AI, focusing on data and technical leadership rather than just algorithms and tools.

- Strategies to mature your AI and ML applications to overcome hurdles and avoid past failures.

- Collaborative opportunities to learn and share experiences with industry leaders and peers.

Join us this October for the AI in Drug Discovery Conference and prepare to be part of the AI revolution in pharmaceutical development.


URLs:
Tickets: https://go.evvnt.com/2449688-0?pid=10018
Brochure: https://go.evvnt.com/2449688-2?pid=10018

Price:
AI in Drug Discovery (EARLY BIRD DISCOUNT UNTIL 09/06/24): USD 2399.00

Speakers: DR BINO JOHN - Director, Computational Biology, Cancer Immunology and Immune Modulation, Boehringer Ingelheim, DR DMITRIY PODOLSKIY - Associate Director, Astellas Pharma, DR PETRINA KAMYA - President, Insilico Medicine Canada Inc., and Global Head of AI Platforms, VP, Insilico Medicine, DR STEPHEN MACKINNON - VP of Digital Chemistry, Recursion Pharmaceuticals, DR VISHNU SRESHT - Director, Precision Labs, Genentech